Navigation Links
Chugai in Medical News

Roche Diabetes Care Announces Unique Coaching Program for Diabetes Educators as Part of Long-Term Commitment to Fight the Disease

... Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in chugai Pharmaceutical, Japan. For more information: www.roche-diagnostics.us . All trademarks used or mentioned in this release are protected by law....

Global Autoimmune Disease Therapeutics Market to Reach $50 Billion by 2015, According to a New Report by Global Industry Analysts

...ce is characterized by participants such as Abbott Laboratories, Amgen Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bristol-Myers Squibb Company, chugai Pharmaceutical Co., Ltd., Elan Corporation, plc, Eli Lilly And Company, F. Hoffmann-La Roche AG, Genentech, Inc., GlaxoSmithKline plc, Johnson & J...

ACTEMRA(R) (tocilizumab) Studies to be Featured at the European League Against Rheumatism (EULAR) Congress

...ates. ACTEMRA is part of a co-development agreement between Roche and chugai Pharmaceutical Co. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional in...

Roche Announces New Co-pay Program in Pennsylvania that Makes It Easier for Patients with Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips

... Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in chugai Pharmaceutical, Japan. For more information: www.roche-diagnostics.us . All trademarks used or mentioned in this release are protected by law....

Roche Announces New Co-pay Program in Florida that Makes It Easier for Patients with Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips

... Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in chugai Pharmaceutical, Japan. For more information: www.roche-diagnostics.us . All trademarks used or mentioned in this release are protected by law....

Roche Announces New Co-Pay Program in California That Makes it Easier for Patients With Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips

... Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in chugai Pharmaceutical, Japan. For more information: www.roche-diagnostics.us . All trademarks used or mentioned in this release are protected by law....

Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology

...e pharmacokinetics and significant reduction in viral load, with good tolerability and safety.(3) Romark recently entered into an agreement granting chugai Pharmaceutical Co., Ltd., a member of the Roche Group, an exclusive license to develop and market nitazoxanide for the treatment of chronic hepatitis ...

Growth Opportunities for Actemra Will Propel Roche to Sixth Position in the Rheumatoid Arthritis Market by 2012

...lines of biological therapy, and reserve agents with other mechanisms of action, such as Orencia and Biogen Idec/Genentech's Rituxan (also marketed by chugai and Zenyaku Kogyo in Japan, and marketed as MabThera in Europe by Roche), largely for TNF-alpha inadequate responders. According to the new report ent...

Global Growth Factors (Blood and Tissue) Market to Reach $52.1 Billion by 2012, According to New Report by Global Industry Analysts

...rtho Inc, Lonza Group, Maxygen Inc, Merck Serono International SA, NsGene A/S, PeproTech Inc, Rentschler Biotechnologie GmbH, F Hoffmann-La Roche Ltd, chugai Pharmaceutical Co Ltd, Genentech Inc, Shantha Biotechnics, Scil Proteins GmbH, and Wockhardt Ltd, among others. The report titled "Growth Fac...

FDA Advisory Committee Recommends Approval of ACTEMRA(R) (tocilizumab) for the Treatment of Rheumatoid Arthritis

...n the United States and Europe. ACTEMRA is part of a co-development agreement with Chugai, a Japanese company. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional indications for rheumatoid arthritis, juvenile idiopathic arthritis and syste...
Chugai in Medical Technology

Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients

...DA). ACTEMRA is part of a co-development agreement between Roche and chugai Pharmaceutical Co. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional in...

Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer

... Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in chugai Pharmaceutical, Japan. For more information: http://www.roche.com . All trademarks used or mentioned in this release are protected by law. ...

Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients

...ates. ACTEMRA is part of a co-development agreement between Roche and chugai Pharmaceutical Co. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional in...

Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)

.... ACTEMRA is part of a co-development agreement between Roche and chugai Pharmaceutical Co. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional in...

New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients

...d States and Europe. ACTEMRA is part of a co-development agreement between Roche and Chugai Pharmaceutical Co. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional indications for rheumatoid arthritis, juvenile idiopathic arthritis and syste...

ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments

...d States and Europe. ACTEMRA is part of a co-development agreement between Roche and Chugai Pharmaceutical Co. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional indications for rheumatoid arthritis, juvenile idiopathic arthritis and syste...

ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies

...n the United States and Europe. ACTEMRA is part of a co-development agreement with Chugai, a Japanese company. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional indications for rheumatoid arthritis, juvenile idiopathic arthritis and syste...

New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients

... the United States and Europe. ACTEMRA is part of a co-development agreement with Chugai, a Japanese company. In April 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, ACTEMRA was approved for the treatment of rheumatoid arthritis, juvenile idiopathic arth...

International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet

...n the United States and Europe. ACTEMRA is part of a co-development agreement with Chugai, a Japanese company. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2006, additional indications for rheumatoid arthritis and systemic-onset juvenile idiopathic a...

Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis

...bition of structural damage in 2008. ACTEMRA is part of a co-development agreement with Chugai, a Japanese company. ACTEMRA was launched in Japan by chugai in June 2005 as a therapy for Castleman's disease. Additional indications for RA and systemic-onset juvenile idiopathic arthritis were also filed in J...
Chugai in Biological Technology

Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan

Chugai Pharmaceutical Gains Rights to Develop and Market Nitazoxanide for the Treatment of Chronic Hepatitis C TAMPA, Fla., Feb. 17 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, and Chugai Pharmaceutical Co. Ltd., a member of the Roche Group, today announced...

Roche Announces Back-to-Basics Approach to Diabetes Care - Simpler is Better

... Group posted sales of 45.6 billion Swiss francs. Genentech (United States) is a wholly owned member of the Roche Group. Roche has a majority stake in chugai Pharmaceutical (Japan). For more information, visit www.roche-diagnostics.us . All trademarks used or mentioned in this release are protected ...

Roche Announces Long-Term Commitment to Tackle Growing Epidemic of Diabetes

... Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in chugai Pharmaceutical, Japan. For more information: www.roche-diagnostics.us . All trademarks used or mentioned in this release are protected by law....

Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer

...nald served as Senior Vice President and Chief Business Officer at Aeterna Zentaris, and, prior to that, Senior Vice President, Business Operations at chugai Pharma USA. At both firms, she had a key role in establishing new directions for the enterprise and facilitating relationships with the financial com...

ACTEMRA(R) (tocilizumab) Studies to be Featured at American College of Rheumatology Annual Scientific Meeting

...in the United States and Europe. ACTEMRA is part of a co-development agreement with Chugai Pharmaceuticals Co. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional indications for rheumatoid arthritis, juvenile idiopathic arthritis and syste...

David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO

...f experience in the pharmaceutical industry, most recently as President and CEO of AEterna Zentaris. Dr. Mazzo also has served as President and CEO of chugai Pharma USA, LLC, the U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan, a member of the Roche Group. Dr. Mazzo replaces Regado co- founder D...

Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development

... on their product development platforms. Prior to joining Chiltern International, Ms. Wood served as the Director, Product Development for Oncology at chugai Pharma USA in San Diego. "We are pleased to welcome Diana to Stason," said Mr. Fan. "As a seasoned business development executive, she has built a h...

Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...BELLO A/S (OMX Nordic Exchange Copenhagen: ALK.B) chugai PHARM CO (Tokyo SE: 4519) DR REDDYS LABS LTD (NYS...) Add ABRAXIS BIOSCIENCE INC (NASDAQ: ABII ) chugai PHARM CO (Tokyo SE: 4519) DR REDDYS LABS LTD (NYS...N ) CARL ZEISS MEDITEC (Frankfurt, Germany: AFX) chugai PHARM CO (Tokyo SE: 4519) CIGNA CORP (NYSE: CI )...

Leading global Big Pharma companies of 2005

... +21% 30 32 Altana (Germany) $2.8 +27% Source: Pharmaceutical Executive , May 2006 * includes sales from acquisition of Japanese company chugai but does not include sales from majority-owned position in Genentech ** merger of Yamanouchi and Fujisawa to become Astellas *** does not include re...
Other Tags
(Date:4/28/2015)... 2015 Georgia State University’s School of ... that will partner with the school on efforts to ... nation that produces more tobacco and has more smokers ... China Tobacco Control Partnership-Tobacco Free Cities, will focus on ... to support tobacco control efforts and where public health ...
(Date:4/28/2015)... 2015 Tools4ever, the market leader ... today that they have been chosen by IT ... Identity and Access Management vendors. IT Central Station ... and Access Management tools by real users in ... analyzed their trends to come up with the ...
(Date:4/28/2015)... 28, 2015 A new survey from ... lung damage, 66 percent of Americans fear brain damage the ... Awareness Month in May, shed light on the need for ... help prevent a stroke. By controlling modifiable risk factors, ... stroke is a “ brain attack ” that occurs when ...
(Date:4/28/2015)... April 28, 2015 A first-in-human ... of Molecular Imaging and Biology showed initial safety, ... generation fluorine-18 labeled small-molecule PSMA inhibitor. The imaging ... in Baltimore, MD by study co-author, Martin G. ... evaluation of [18F]DCFPyL demonstrated a number of important ...
(Date:4/28/2015)... Colorado spine surgeon Donald Corenman, MD, ... popular spine education website NECKANDBACK.COM and his ... Media. This website has been redesigned to help patients ... spine, causes of neck and back pain, and conditions ... and personally answers questions in the neck and back ...
Breaking Medicine News(10 mins):Health News:Georgia State Names Partner Cities For Tobacco Control Project 2Health News:Tools4ever Chosen as Part of “Top Identity and Access Management Tools - 2015 Edition” 2Health News:National Stroke Association Survey Reveals Americans Fear Brain Damage the Most, but Few Take the Necessary Steps to Prevent a Stroke 2Health News:National Stroke Association Survey Reveals Americans Fear Brain Damage the Most, but Few Take the Necessary Steps to Prevent a Stroke 3Health News:Second Generation 18F-labeled Prostate-Specific Membrane Antigen (PSMA) Targeted Imaging Agent Found to be Highly Sensitive in Detecting Prostate Cancer 2Health News:Second Generation 18F-labeled Prostate-Specific Membrane Antigen (PSMA) Targeted Imaging Agent Found to be Highly Sensitive in Detecting Prostate Cancer 3Health News:Colorado Spine Surgeon Donald Corenman, MD, DC Launches Updated Version of NECKANDBACK.COM and Popular Back Pain Forum ASKSPINEDOC.COM 2Health News:Colorado Spine Surgeon Donald Corenman, MD, DC Launches Updated Version of NECKANDBACK.COM and Popular Back Pain Forum ASKSPINEDOC.COM 3
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
(Date:4/1/2015)... , Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... Wocket smart wallets is underway to early access pre-order ... group includes usage at retail outlets including Walmart, Target, ... Users report Wocket was accepted at all outlets and ...
(Date:3/31/2015)... YORK , March 31, 2015  Elephant Talk ... "Company"), a global provider of Software Defined Network Architecture ... today announced total revenue of approximately $20.4 million for ... a restated $19.5 million for the year ended December ... calendar 2014, the Company had completed its multi-year transition ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
Other Contents